ALDEA Pharmaceuticals is developing a number of small-molecule modulators of the aldehyde dehydrogenase enzyme (ALDH) superfamily. This proprietary scientific approach was originally discovered by Stanford University researchers and exclusively licensed to Aldea. With its ALDH platform, ALDEA has the unique opportunity to pursue novel targets across multiple therapeutic areas to address significant unmet medical needs.
Aldea is the first company targeting aldehyde metabolism dysfunction. Aldehyde metabolism dysfunction is associated with a variety of diseases from acute alcohol toxicity to orphan indications such as Fanconi anemia. Through its groundbreaking discoveries and deep expertise in aldehyde metabolism, Aldea aspires to improve the lives of patients suffering from meaningful medical disorders.